Related Experiment Video
Updated: May 18, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Disease-specific therapy of idiopathic inflammatory demyelinating disorders
Mohsen Khoshnam1, Mark S Freedman
1Multiple Sclerosis Research Unit, The Ottawa Hospital General Campus, University of Ottawa, Box 606 MS Clinic, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada. mkhoshnam@toh.on.ca
Abstract:
Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options for their patients. For two of these conditions, multiple sclerosis and neuromyelitis optica, there are now several possible therapies in an ever-evolving field. This review will touch on the various idiopathic inflammatory demyelinating disorders and discuss the various treatment options currently available.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease
Diphtheria
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
